Irinotecan in combination with new agents

European Journal of Cancer, Supplement

Volumn 2, Issue 7, 2004, Pages 14-20

  Vanhoefer, U ^a   Rougier, P ^b   Borner, M ^c   Munoz A ^d   Van Laethem, J L ^e   Sobrero, A ^f  

^a Department of Internal Medicine ^*  (Germany)

^b HÔPITAL AMBROISE PARÉ   (France)

^c UNIVERSITY OF BERN   (Switzerland)

^d HOSPITAL DE CRUCES   (Spain)

^e ERASME HOSPITAL   (Belgium)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Bevacizumab; Capecitabine; Celecoxib; Cetuximab; Colorectal cancer; Irinotecan

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CELECOXIB; CETUXIMAB; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VINCRISTINE;

ALOPECIA; ASPIRATION PNEUMONIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SEPSIS; STOMATITIS; STROKE; THROMBOSIS;

EID: 2642565940     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.04.010     Document Type: Article

References (41)

1. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343:2000;905-914
2. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:2000;1041-1047
3. Köhne C.H., Van Cutsem E., Wils J.A., et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of the EORTC GI Group study 40986. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1018)
4. Vanhoefer U., Harstrick A., Achterrath W., Cao S., Seeber S., Rustum Y.M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19:2001;1501-1518
5. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur. J. Cancer. 38(Suppl 2):2002;15-20
6. Tewes M., Schleucher N., Achterrath W., et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study dagger. Ann. Oncol. 14:2003;1442-1448
7. Muñoz A., Salut A., Escudero P., et al. Irinotecan (CPT-11) and capecitabine (C) as first line treatment of locally advanced or metastatic colorectal cancer (CRC. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1271)
8. Borner M.M., Dietrich D., Popescu R., et al. A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1068)
9. Costa C., Soares R., Reis-Filho J.S., Leitao D., Amendoeira I., Schmitt F.C. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J. Clin. Pathol. 55:2002;429-434
10. Denkert C., Winzer K.J., Muller B.M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 97:2003;2978-2987
11. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 33:2002;708-714
12. Chen Y.J., Wang L.S., Wang P.H., et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol. Oncol. 88:2003;379-385
13. Buecher B., Heymann M.F., Lievre A., et al. Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvement. Aliment. Pharmacol. Ther. 18:2003;731-740
14. Konno H., Baba M., Shoji T., Ohta M., Suzuki S., Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin. Exp. Metatasis. 19:2002;527-534
15. Xiong B., Sun T.J., Yuan H.Y., Hu M.B., Cheng F.L. Cyclooxygenase-2 expression and angiogenesis in colorectal cancer. World J. Gastroenterol. 9:2003;1237-1240
16. Yoshimoto T., Takahashi Y., Kinoshita T., Sakashita T., Inoue H., Tanabe T. Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv. Exp. Med. Biol. 507:2002;403-407
17. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:2000;1946-1952
18. Hashitani S., Urade M., Nishimura N., et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol. 23:2003;665-672
19. Trifan O.C., Durham W.F., Salazar V.S., et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62:2002;5778-5784
20. Blanke C., Benson A.B., Dragovich T., et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 505)
21. Sweeney C., Seitz D., Ansari R., et al. A phase II trial of irinotecan (I), 5-fluorouracil (F), leucovorin (L) (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer: a Hoosier Oncology Group study. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 2235)
22. Pan C., Loehrer P.J., Juliar B., Ansari R., Pletcher W., Sweeney C. A phase II trial of irinotecan (I), 5-fluorouracil (F), leucovorin (L) (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer: a Hoosier Oncology Group Study. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1347)
23. Chaudhary N., Hruska K. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, FGF-2 in osteoblastic cells. Cell Biochem. 81:2001;304-311
24. Baker N., Yu S. The EGF receptor defines domains of cell cycle progression and survival to regulate cell number in the developing Drosophila eye. Cell. 104:2001;699-708
25. Jost M., Kari C., Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 10:2000;505-510
26. McKay J.A., Murray L.J., Curran S., et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur. J. Cancer. 38:2002;2258-2264
27. Hooper A.T., Ellis L.M., Waksal H., Hicklin D.J. Expression of epidermal growth factor receptor in human colorectal adenocarcinomas: an immunohistochemical study. Proc. Am. Assoc. Cancer Res. 42:2001;. (Abstract 2824)
28. Cunningham D., Humblet Y., Siena S., et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1012). Updated information from 2003 virtual meeting at www.asco.org
29. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 37:2001;S9-S15
30. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR. Proc. Am. Soc. Clin. Oncol. 20:2001;. (Abstract 7)
31. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8:2002;994-1003
32. Delbaldo C., Pierga J.-.Y., Dieras V., et al. Phase I pharmacokinetic [PK] evaluation of the interaction between cetuximab and irinotecan in patients with EGFR positive advanced solid tumors. Proc. Am. Assoc. Cancer Res. 2003;. (Abstract 5353)
33. Saltz L., Meropol N.J., Loehrer P.J., Waksal H., Needle M.N., Mayer R.J. Single agent IMC-C225 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 504)
34. Schöffski P., Lutz M., Folprecht G., et al. Cetuximab (C225) plus irinotecan (CPT-11) plus infusional5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC) that expresses epidermal growth factor receptor (EGFR. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 633)
35. van Laethem J.-.L., Raoul J.-.L., Mitry E., et al. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1058)
36. Rosenberg A.H., Loehrer P.J., Needle M.N., et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 536)
37. Go R.S., Horstmann A.L. Circulating basic fibroblast growth factor (B-FGF) and vascular endothelial growth factor (VEGF) levels in cancer patients: implications for anti-angiogenic therapy. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 3031)
38. Witte D., Thomas A., Ali N., Carlson N., Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res. 22:2002;1463-1466
39. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:2003;60-65
40. Giantonio B.J., Levy D., O'Dwyer P.J., Meropol N.J., Catalano P.J., Benson A.B. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) study E2200. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1024)
41. Hurwitz H., Fehrenbacher L., Cartwright T., et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 3646)